Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 6—June 2021

Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA

Mariana M. Lanata1, Huanyu Wang, Kathy Everhart, Melisa Moore-Clingenpeel, Octavio Ramilo, and Amy LeberComments to Author 
Author affiliation: Nationwide Children’s Hospital, Columbus, Ohio, USA

Main Article

Table 6

Multivariable models for assessing adjusted risk factors for pediatric intensive care unit admission in children infected with Mycoplasma pneumoniae, Ohio, USA, 2015–2019*

Model aOR (95% CI) p value
Model 1
Macrolide resistance 5.111 (1.248–20.926) 0.0233
Underlying conditions
4.238 (1.68–10.694)
Model 2
Macrolide resistance 4.964 (1.247–19.762) 0.023
Any previous visits
3.625 (1.273–10.323)
Model 3
Macrolide resistance 4.895 (1.227–19.532) 0.0245
Abnormal respiratory exam
5.164 (1.37–19.461)
Model 4
Macrolide resistance 4.969 (1.241–19.906) 0.0235
Any previous antimicrobial drugs
3.076 (1.332–7.101)
Model 5
Macrolide resistance 4.911 (1.237–19.499) 0.0237
Any previous nonmacrolide antimicrobial drugs 2.717 (1.184–6.234) 0.0183

*Bold type indicates statistical significance. aOR, adjusted odds ratio.

Main Article

1Current affiliation: Marshall University, Huntington, West Virginia, USA.

Page created: March 30, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.